8-K

   1




                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                         Date of Report AUGUST 14, 2000


                             BARR LABORATORIES, INC.
             (Exact name of registrant as specified in its charter)




         New York                      1-9860                 22-1927534

(State or other jurisdiction        (Commission             (IRS Employer
     of incorporation)              File Number)          Identification No.)




Two Quaker Road, P.O. Box 2900, Pomona, New York          10970-0519

    (Address of principal executive offices)              (Zip code)

                                 (914) 362-1100

              (Registrant's telephone number, including area code)

                                       1
   2
                             BARR LABORATORIES, INC.


                      CURRENT REPORT DATED AUGUST 14, 2000


Item 5. Other Events

         See attached Exhibit 99.2, press release announcing that the U.S. Court
         of Appeals, Federal Circuit in Washington, D.C, ruled in favor of the
         Company's "double patenting" claim against the patents protecting Eli
         Lilly's Prozac(R) anti-depressant. The decision strikes down the patent
         that would have expired in December 2003.





Item 7. Financial Statements and Exhibits

(c)     Exhibit Number     Exhibit

        99.2               Registrant's August 9, 2000 press release announcing
                           that the U.S. Court of Appeals, Federal Circuit in
                           Washington, D.C, ruled in favor of the Company's
                           "double patenting" claim against the patents
                           protecting Eli Lilly's Prozac(R) anti-depressant. The
                           decision strikes down the patent that would have
                           expired in December 2003.

                                       2
   3
                             BARR LABORATORIES, INC.


                      CURRENT REPORT DATED AUGUST 14, 2000



                                   SIGNATURES


Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                             BARR LABORATORIES, INC.












Date:  August 14, 2000              /S/ William T. McKee
                                    --------------------
                                    William T. McKee
                                    Chief Financial Officer

                                       3

EX-99.2

   1
                                                                    Exhibit 99.2

2 Quaker Road, P.O. Box 2900                           N E W S   R E L E A S E
Pomona, NY 10970
914-362-1100


CONTACT: Carol Cox, 914-348-6808            EMAIL: ccox@barrlabs.com

PROZAC(R) PATENT RULED INVALID BY U.S. COURT OF APPEALS
Ruling A Victory For Consumers;
Generic Launch Could Come As Early as February 2001

Pomona, NY, August 9, 2000 -- Barr Laboratories, Inc. (NYSE-BRL) today said the
U.S. Court of Appeals, Federal Circuit in Washington, D.C, has ruled in favor
of the Company's "double patenting" claim against the patents protecting Eli
Lilly's Prozac(R) anti-depressant. The decision strikes down the patent that
would have expired in December 2003. The Company said this decision should clear
the way for generic competition as early as February 2001.

The Court of Appeals, however, affirmed the decision of the lower court, which
rejected Barr's "best mode" arguments with respect to the patent expiring in
February 2001.

"We are pleased that after a thorough review the Court recognizes the importance
of restricting add-on patents solely designed to extend the patent life of
blockbuster drugs at the expense of consumers," said Bruce L. Downey, Barr's
Chairman and CEO.

Barr's argument before the Appeals court involved the claims of "double
patenting" and "best mode". Barr filed an Abbreviated New Drug Application
(ANDA) for a generic version of Prozac and charged that two patents protecting
Prozac from competition are invalid. In a pre-trial hearing in January 1999,
District Court Judge Sarah Barker, U.S. District Court, Southern District of
Indiana had dismissed these two claims. Prior to the start of the district
trial, both parties agreed to take the case directly to the Appeals Court.
Barr's challenge of the Prozac patents was initiated in April 1996.

Barr Laboratories, Inc. is engaged in the development, manufacture and marketing
of generic and proprietary pharmaceuticals.

[EDITOR'S ADVISORY: Barr Laboratories, Inc. news releases are available free of
charge through PR Newswire's News On-Call fax service. For a menu of Barr's
previous releases, or to receive a specific release via fax call : 800-758-5804
- -- ext. 089750. For complete indications, warnings and contraindications,
contact Barr Laboratories' Professional Services Department at 1-800-Barr Lab.]

Safe Harbor Statement: To the extent that any statements made in this release
contain information that is not historical, these statements are essentially
forward looking and are subject to risks and uncertainties, including the extent
and outcome of litigation, the difficulty of predicting FDA approvals,
acceptance and demand for new pharmaceutical products, the impact of competitive
products and pricing, new product development and launch, availability of raw
materials, the regulatory environment and other risks detailed from time-to-time
in the Company's filings with the Securities and Exchange Commission.

                                      # # #
                                        4